Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1100101

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1100101

APAC Medication Assisted (MAT) Treatment Market - Industry Trends and Forecast to 2029

PUBLISHED:
PAGES: 273 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 3500
PDF (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

The Asia-Pacific medication-assisted treatment (MAT) market is projected to register a substantial CAGR of 10.5% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2019, the base year of calculation is 2021, and the forecast period is 2022 to 2029.

Market Segmentation:

Asia-Pacific Medication-Assisted Treatment (MAT) Market, By Type (Medication and Therapy), Products (Buprenorphine and Naloxone, Naltrexone, Buprenorphine, Methadone, Naloxone, Disulfiram, and Acamprosate), Drug Type (Generics and Branded), Dosage Form (Immediate Release and Extended Release), Route of Administration (Oral, Parenteral, and Others), Population Type (Adults and Teenage), End User (Rehabilitation Clinics, Hospitals, Specialty Centres, Homecare, and Others) Distribution Channel (Hospital Pharmacy, Direct Tender, Retail Pharmacy, Online Pharmacy, and Others), Country (China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific) Industry Trends and Forecast to 2029

Some of the major factors contributing to the growth of Asia-Pacific medication-assisted treatment (MAT) are:

The rise in incidence of alcohol use disorder and opioid use disorders

Increasing awareness of MAT

Market Players:

Some of the major players operating in the Asia-Pacific medication-assisted treatment (MAT) market are:

Indivior PLC

Sun Pharmaceutical Industries Ltd.

Taj Pharmaceuticals Limited

Hikma Pharmaceuticals PLC

Pfizer Inc.

Glenmark Pharmaceutical Inc.

Viatris Inc.

Alvogen

Accord Healthcare

Teva Pharmaceutical Industries Ltd.

Dr. Reddy's Laboratories Ltd.

Amneal Pharmaceuticals LLC. among others

TABLE OF CONTENTS

1 INTRODUCTION 49

  • 1.1 OBJECTIVES OF THE STUDY 49
  • 1.2 MARKET DEFINITION 49
  • 1.3 OVERVIEW OF ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET 49
  • 1.4 CURRENCY AND PRICING 52
  • 1.5 LIMITATIONS 52
  • 1.6 MARKETS COVERED 53

2 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SEGMENTATION 57

  • 2.1 MARKETS COVERED 57
  • 2.2 GEOGRAPHICAL SCOPE 58
  • 2.3 YEARS CONSIDERED FOR THE STUDY 59
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 60
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 63
  • 2.6 MULTIVARIATE MODELLING 64
  • 2.7 PRODUCT SEGMENT LIFELINE CURVE 64
  • 2.8 DBMR MARKET POSITION GRID 65
  • 2.9 VENDOR SHARE ANALYSIS 67
  • 2.10 MARKET END USER COVERAGE GRID 68
  • 2.11 SECONDARY SOURCES 69

3 EXECUTIVE SUMMARY 70

4 PREMIUM INSIGHTS 74

  • 4.1 EPIDEMIOLOGY 75
  • 4.2 PESTEL 76
  • 4.3 PORTER'S FIVE FORCES MODEL 77
  • 4.4 ANNUAL INCIDENCE OF SUBJECTS ENTERING MEDICATION-ASSISTED TREATMENT IN ALCOHOL, OPIOID USE DISORDER, AND OPIOID OVERDOSE PREVENTION (2021) 78
  • 4.5 ANNUAL NUMBER OF TREATMENTS WITH CLONIDINE AND WITH LOFEXIDINE IN OPIOID USE DISORDER AND OPIOID OVERDOSE PREVENTION (2021) 78
  • 4.6 ANNUAL INCIDENCE OF INDIVIDUALS RE-ENTERING MEDICATION-ASSISTED TREATMENT. FOR EXAMPLE, SOMEONE MAY DROP OUT OF TREATMENT AND RESTART TREATMENT LATER (2021) 79
  • 4.7 ANNUAL USE OF NALTREXONE INJECTION AS PART OF TREATMENT FOR THE INITIAL WITHDRAWAL FROM OPIOIDS, AND ANNUAL MAINTENANCE THERAPY USING NALTREXONE INJECTION (2021) 79
  • 4.8 PIPELINE ANALYSIS FOR MEDICATION-ASSISTED TREATMENT (MAT) MARKET 80

5 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT MARKET: REGULATIONS 81

6 MARKET OVERVIEW 84

  • 6.1 DRIVERS 86
    • 6.1.1 THE RISE IN INCIDENCE OF ALCOHOL USE DISORDER AND OPIOID USE DISORDERS 86
    • 6.1.2 THE FUNDING BY THE GOVERNMENT FOR MEDICATION-ASSISTED TREATMENT (MAT) 87
    • 6.1.3 THE RISE IN THE POPULATION RECEIVING MEDICATION-ASSISTED TREATMENT (MAT) AND MEDICATION-ASSISTED AWARENESS PROGRAMMESMEDICATION-ASSISTED TREATMENT (MAT) 87
    • 6.1.4 USE OF REIMBURSEMENT FOR MEDICATION-ASSISTED TREATMENT (MAT) 88
  • 6.2 RESTRAINTS 89
    • 6.2.1 SIDE EFFECTS OF DRUGS USED IN MEDICATION-ASSISTED TREATMENT (MAT) 89
    • 6.2.2 ETHICAL ISSUES RELATED TO USE OF MEDICATION-ASSISTED TREATMENTMEDICATION-ASSISTED TREATMENT (MAT) 89
    • 6.2.3 RISE IN PRODUCT RECALLS 89
  • 6.3 OPPORTUNITIES 90
    • 6.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 90
    • 6.3.2 RISE IN HEALTHCARE EXPENDITURE 91
  • 6.4 CHALLENGES 91
    • 6.4.1 THE LACK OF SKILLED PROFESSIONALS, REQUIRED FOR MEDICATION-ASSISTED TREATMENT 91
    • 6.4.2 STRINGENT REGULATIONS 92
    • 6.4.3 DISCONTINUATION OF MEDICATION-ASSISTED TREATMENT (MAT) 93

7 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE 94

  • 7.1 OVERVIEW 95
  • 7.2 MEDICATION 98
    • 7.2.1 OPIOID DEPENDENCY MEDICATION 99
      • 7.2.1.1 BUPRENORPHINE AND NALOXONE 99
      • 7.2.1.2 BUPRENORPHINE 99
      • 7.2.1.3 METHADONE 99
      • 7.2.1.4 NALTREXONE 100
    • 7.2.2 ALCOHOL USE DISORDER MEDICATIONS 100
      • 7.2.2.1 NALTREXONE 100
      • 7.2.2.2 DISULFIRAM 100
      • 7.2.2.3 ACAMPROSATE 100
    • 7.2.3 OPIOID OVERDOSE PREVENTION MEDICATION 100
      • 7.2.3.1 NALOXONE 101

  • 7.3 THERAPY 101
    • 7.3.1 BEHAVIORAL THERAPY 102
    • 7.3.2 EDUCATIONAL THERAPY 102
    • 7.3.3 COUNSELLING 102
    • 7.3.4 VOCATIONAL THERAPY 102
    • 7.3.5 OTHERS 103

8 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS 104

  • 8.1 OVERVIEW 105
  • 8.2 BUPRENORPHINE AND NALOXONE 108
  • 8.3 NALTREXONE 108
  • 8.4 BUPRENORPHINE 110
  • 8.5 METHADONE 110
  • 8.6 NALOXONE 111
  • 8.7 DISULFIRAM 112
  • 8.8 ACAMPROSATE 113

9 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE 114

  • 9.1 OVERVIEW 115
  • 9.2 GENERICS 118
  • 9.3 BRANDED 118
    • 9.3.1 SUBOXONE 119
    • 9.3.2 VIVITROL 119
    • 9.3.3 BUTRANS 119
    • 9.3.4 ZUBSOLV 120
    • 9.3.5 PROBUPHINE 120
    • 9.3.6 OTHERS 120

10 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM 121

  • 10.1 OVERVIEW 122
  • 10.2 IMMEDIATE RELEASE 125
  • 10.3 EXTENDED RELEASE 125

11 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION 127

  • 11.1 OVERVIEW 128
  • 11.2 ORAL 131
    • 11.2.1 TABLET 132
    • 11.2.2 SUBLINGUAL FILM 132
    • 11.2.3 OTHERS 132
  • 11.3 PARENTERAL 132
    • 11.3.1 SOLUTION 133
    • 11.3.2 SUSPENSION 133
  • 11.4 OTHERS 134

12 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE 135

  • 12.1 OVERVIEW 136
  • 12.2 ADULTS 139
  • 12.3 TEENAGE 139

13 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER 141

  • 13.1 OVERVIEW 142
  • 13.2 REHABILITATION CLINICS 145
  • 13.3 HOSPITALS 145
  • 13.4 SPECIALTY CENTERS 146
  • 13.5 HOMECARE 147
  • 13.6 OTHERS 148

14 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL 149

  • 14.1 OVERVIEW 150
  • 14.2 HOSPITAL PHARMACY 153
  • 14.3 DIRECT TENDER 153
  • 14.4 RETAIL PHARMACY 154
  • 14.5 ONLINE PHARMACY 155
  • 14.6 OTHERS 156

15 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION 157

  • 15.1 ASIA-PACIFIC 158
    • 15.1.1 CHINA 168
    • 15.1.2 JAPAN 173
    • 15.1.3 INDIA 178
    • 15.1.4 AUSTRALIA 183
    • 15.1.5 SOUTH KOREA 188
    • 15.1.6 SINGAPORE 193
    • 15.1.7 MALAYSIA 198
    • 15.1.8 THAILAND 203
    • 15.1.9 INDONESIA 208
    • 15.1.10 PHILIPPINES 213
    • 15.1.11 VIETNAM 218
    • 15.1.12 REST OF ASIA-PACIFIC 223

16 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY LANDSCAPE 224

  • 16.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 224

17 SWOT ANALYSIS 225

18 COMPANY PROFILE 226

  • 18.1 TEVA PHARMACEUTICAL INDUSTRIES LTD. (2021) 226
    • 18.1.1 COMPANY SNAPSHOT 226
    • 18.1.2 REVENUE ANALYSIS 227
    • 18.1.3 COMPANY SHARE ANALYSIS 227
    • 18.1.4 PRODUCT PORTFOLIO 227
    • 18.1.5 RECENT DEVELOPMENTS 228
  • 18.2 INDIVOR PLC (2021) 229
    • 18.2.1 COMPANY SNAPSHOT 229
    • 18.2.2 REVENUE ANALYSIS 229
    • 18.2.3 COMPANY SHARE ANALYSIS 230
    • 18.2.4 PRODUCT PORTFOLIO 230
    • 18.2.5 RECENT DEVELOPMENTS 231
  • 18.3 VIATRIS INC (2021) 232
    • 18.3.1 COMPANY SNAPSHOT 232
    • 18.3.2 REVENUE ANALYSIS 232
    • 18.3.3 COMPANY SHARE ANALYSIS 233
    • 18.3.4 PRODUCT PORTFOLIO 233
    • 18.3.5 RECENT DEVELOPMENTS 233

  • 18.4 SUN PHARMACEUTICAL INDUSTRIES LTD (2021) 234
    • 18.4.1 COMPANY SNAPSHOT 234
    • 18.4.2 REVENUE ANALYSIS 234
    • 18.4.3 COMPANY SHARE ANALYSIS 235
    • 18.4.4 PRODUCT PORTFOLIO 235
    • 18.4.5 RECENT DEVELOPMENTS 235
  • 18.5 ALKERMES (2021) 236
    • 18.5.1 COMPANY SNAPSHOT 236
    • 18.5.2 REVENUE ANALYSIS 236
    • 18.5.3 COMPANY SHARE ANALYSIS 237
    • 18.5.4 PRODUCT PORTFOLIO 237
    • 18.5.5 RECENT DEVELOPMENTS 238
  • 18.6 PURDUE PHARMA L.P. (2021) 239
    • 18.6.1 COMPANY SNAPSHOT 239
    • 18.6.2 PRODUCT PORTFOLIO 239
    • 18.6.3 RECENT DEVELOPMENTS 239
  • 18.7 PFIZER (2021) 240
    • 18.7.1 COMPANY SNAPSHOT 240
    • 18.7.2 REVENUE ANALYSIS 240
    • 18.7.3 PRODUCT PORTFOLIO 241
    • 18.7.4 RECENT DEVELOPMENTS 241
  • 18.8 GLENMARK PHARMACEUTICAL INC (2021) 242
    • 18.8.1 COMPANY SNAPSHOT 242
    • 18.8.2 REVENUE ANALYSIS 242
    • 18.8.3 PRODUCT PORTFOLIO 243
    • 18.8.4 RECENT DEVELOPMENTS 243
  • 18.9 DR. REDDY'S LABORATORIES LTD (2021) 244
    • 18.9.1 COMPANY SNAPSHOT 244
    • 18.9.2 REVENUE ANALYSIS 244
    • 18.9.3 PRODUCT PORTFOLIO 245
    • 18.9.4 RECENT DEVELOPMENTS 245
  • 18.10 ALVOGEN (2021) 246
    • 18.10.1 COMPANY SNAPSHOT 246
    • 18.10.2 PRODUCT PORTFOLIO 246
    • 18.10.3 RECENT DEVELOPMENTS 246
  • 18.11 ADAMIS PHARMACEUTICALS CORPORATION (2021) 247
    • 18.11.1 COMPANY SNAPSHOT 247
    • 18.11.2 REVENUE ANALYSIS 247
    • 18.11.3 PRODUCT PORTFOLIO 248
    • 18.11.4 RECENT DEVELOPMENTS 248
  • 18.12 ACCORD HEALTHCARE (A SUBSIDIARY OF INTAS PHARMACEUTICALS) 249
    • 18.12.1 COMPANY SNAPSHOT 249
    • 18.12.2 PRODUCT PORTFOLIO 249
    • 18.12.3 RECENT DEVELOPMENTS 250
  • 18.13 AMNEAL PHARMACEUTICALS LLC (2021) 251
    • 18.13.1 COMPANY SNAPSHOT 251
    • 18.13.2 REVENUE ANALYSIS 251
    • 18.13.3 PRODUCT PORTFOLIO 252
    • 18.13.4 RECENT DEVELOPMENTS 252
  • 18.14 AMERICAN ADDICTION CENTERS (2021) 253
    • 18.14.1 COMPANY SNAPSHOT 253
    • 18.14.2 PRODUCT PORTFOLIO 253
    • 18.14.3 RECENT DEVELOPMENTS 253
  • 18.15 HIKMA PHARMACEUTICALS PLC (2021) 254
    • 18.15.1 COMPANY SNAPSHOT 254
    • 18.15.2 REVENUE ANALYSIS 254
    • 18.15.3 PRODUCT PORTFOLIO 255
    • 18.15.4 RECENT DEVELOPMENTS 255
  • 18.16 LANNETT (2021) 256
    • 18.16.1 COMPANY SNAPSHOT 256
    • 18.16.2 REVENUE ANALYSIS 256
    • 18.16.3 PRODUCT PORTFOLIO 257
    • 18.16.4 RECENT DEVELOPMENT 257
  • 18.17 MALLINCKRODT (2021) 258
    • 18.17.1 COMPANY SNAPSHOT 258
    • 18.17.2 REVENUE ANALYSIS 258
    • 18.17.3 PRODUCT PORTFOLIO 259
    • 18.17.4 RECENT DEVELOPMENT 259
  • 18.18 OREXO US INC (A SUBSIDIARY OF OREXO, INC) (2021) 260
    • 18.18.1 COMPANY SNAPSHOT 260
    • 18.18.2 REVENUE ANALYSIS 260
    • 18.18.3 PRODUCT PORTFOLIO 261
    • 18.18.4 RECENT DEVELOPMENT 261
  • 18.19 PINNACLE TREATMENT CENTERS 262
    • 18.19.1 COMPANY SNAPSHOT 262
    • 18.19.2 PRODUCT PORTFOLIO 262
    • 18.19.3 RECENT DEVELOPMENT 262

  • 18.20 RECOVERY CENTERS OF AMERICA 263
    • 18.20.1 COMPANY SNAPSHOT 263
    • 18.20.2 PRODUCT PORTFOLIO 263
    • 18.20.3 RECENT DEVELOPMENTS 264
  • 18.21 TAJ PHARMACEUTICALS LIMITED 265
    • 18.21.1 COMPANY SNAPSHOT 265
    • 18.21.2 PRODUCT PORTFOLIO 265
    • 18.21.3 RECENT DEVELOPMENTS 265
  • 18.22 TITAN PHARMACEUTICALS (2021) 266
    • 18.22.1 COMPANY SNAPSHOT 266
    • 18.22.2 REVENUE ANALYSIS 266
    • 18.22.3 PRODUCT PORTFOLIO 267
    • 18.22.4 RECENT DEVELOPMENTS 267
  • 18.23 VISTAPHARM, INC (A SUBSIDIARY OF VERTICE PHARMA, LLC. (2021)) 268
    • 18.23.1 COMPANY SNAPSHOT 268
    • 18.23.2 PRODUCT PORTFOLIO 268
    • 18.23.3 RECENT DEVELOPMENTS 268

19 QUESTIONNAIRE 269

20 RELATED REPORTS 273

LIST OF TABLES

  • TABLE 1 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 74
  • TABLE 2 ASIA PACIFIC MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 75
  • TABLE 3 ASIA PACIFIC MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 76
  • TABLE 4 ASIA PACIFIC OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 76
  • TABLE 5 ASIA PACIFIC ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 77
  • TABLE 6 ASIA PACIFIC OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 78
  • TABLE 7 ASIA PACIFIC THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 79
  • TABLE 8 ASIA PACIFIC THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 79
  • TABLE 9 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION) 84
  • TABLE 10 ASIA PACIFIC BUPRENORPHINE AND NALOXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 85
  • TABLE 11 ASIA PACIFIC NALTREXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 86
  • TABLE 12 ASIA PACIFIC BUPRENORPHINE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 87
  • TABLE 13 ASIA PACIFIC METHADONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 88
  • TABLE 14 ASIA PACIFIC NALOXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 89
  • TABLE 15 ASIA PACIFIC DISULFIRAM IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 90
  • TABLE 16 ASIA PACIFIC ACAMPROSATE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 90
  • TABLE 17 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 94
  • TABLE 18 ASIA PACIFIC GENERICS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 95
  • TABLE 19 ASIA PACIFIC BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 96
  • TABLE 20 ASIA PACIFIC BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 96
  • TABLE 21 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION) 101
  • TABLE 22 ASIA PACIFIC IMMEDIATE RELEASE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 102
  • TABLE 23 ASIA PACIFIC EXTENDED RELEASE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 103
  • TABLE 24 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 107
  • TABLE 25 ASIA PACIFIC ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 108
  • TABLE 26 ASIA PACIFIC ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 109
  • TABLE 27 ASIA PACIFIC PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 110
  • TABLE 28 ASIA PACIFIC PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 110
  • TABLE 29 ASIA PACIFIC OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 111
  • TABLE 30 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 115
  • TABLE 31 ASIA PACIFIC ADULTS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 116
  • TABLE 32 ASIA PACIFIC TEENAGE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 117
  • TABLE 33 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION) 121
  • TABLE 34 ASIA PACIFIC REHABILITATION CLINICS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 122
  • TABLE 35 ASIA PACIFIC HOSPITALS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 123
  • TABLE 36 ASIA PACIFIC SPECIALTY CENTERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 124
  • TABLE 37 ASIA PACIFIC HOMECARE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 124
  • TABLE 38 ASIA PACIFIC OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 125
  • TABLE 39 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 129
  • TABLE 40 ASIA PACIFIC HOSPITAL PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 130
  • TABLE 41 ASIA PACIFIC DIRECT TENDER IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 131
  • TABLE 42 ASIA PACIFIC RETAIL PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 132
  • TABLE 43 ASIA PACIFIC ONLINE PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 132
  • TABLE 44 ASIA PACIFIC OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION) 133
  • TABLE 45 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 140
  • TABLE 46 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 140
  • TABLE 47 ASIA-PACIFIC MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 140
  • TABLE 48 ASIA-PACIFIC OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 141
  • TABLE 49 ASIA-PACIFIC ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 141
  • TABLE 50 ASIA-PACIFIC OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 141
  • TABLE 51 ASIA-PACIFIC THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 141
  • TABLE 52 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION) 142
  • TABLE 53 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 142
  • TABLE 54 ASIA-PACIFIC BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 142
  • TABLE 55 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION) 143
  • TABLE 56 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 143
  • TABLE 57 ASIA-PACIFIC ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 143
  • TABLE 58 ASIA-PACIFIC PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 143
  • TABLE 59 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 144
  • TABLE 60 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION) 144
  • TABLE 61 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 144
  • TABLE 62 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 145
  • TABLE 63 CHINA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 145
  • TABLE 64 CHINA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 145
  • TABLE 65 CHINA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 146
  • TABLE 66 CHINA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 146
  • TABLE 67 CHINA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 146
  • TABLE 68 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION) 147
  • TABLE 69 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 147
  • TABLE 70 CHINA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 147
  • TABLE 71 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION) 148
  • TABLE 72 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 148
  • TABLE 73 CHINA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 148
  • TABLE 74 CHINA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 148
  • TABLE 75 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 149
  • TABLE 76 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION) 149
  • TABLE 77 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 149
  • TABLE 78 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 150
  • TABLE 79 JAPAN MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 150
  • TABLE 80 JAPAN OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 150
  • TABLE 81 JAPAN ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 151
  • TABLE 82 JAPAN OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 151
  • TABLE 83 JAPAN THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 151
  • TABLE 84 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION) 152
  • TABLE 85 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 152
  • TABLE 86 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION) 152
  • TABLE 87 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 153
  • TABLE 88 JAPAN ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 153
  • TABLE 89 JAPAN PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 153
  • TABLE 90 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 153
  • TABLE 91 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION) 154
  • TABLE 92 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 154
  • TABLE 93 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 155
  • TABLE 94 INDIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 155
  • TABLE 95 INDIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 155
  • TABLE 96 INDIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 156
  • TABLE 97 INDIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 156
  • TABLE 98 INDIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 156
  • TABLE 99 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION) 157
  • TABLE 100 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 157
  • TABLE 101 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION) 157
  • TABLE 102 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 158
  • TABLE 103 INDIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 158
  • TABLE 104 INDIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 158
  • TABLE 105 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 158
  • TABLE 106 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION) 159
  • TABLE 107 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 159
  • TABLE 108 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 160
  • TABLE 109 AUSTRALIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 160
  • TABLE 110 AUSTRALIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 160
  • TABLE 111 AUSTRALIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 161
  • TABLE 112 AUSTRALIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 161
  • TABLE 113 AUSTRALIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 161
  • TABLE 114 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION) 162
  • TABLE 115 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 162
  • TABLE 116 AUSTRALIA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 162
  • TABLE 117 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION) 163
  • TABLE 118 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 163
  • TABLE 119 AUSTRALIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 163
  • TABLE 120 AUSTRALIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 163
  • TABLE 121 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 164
  • TABLE 122 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION) 164
  • TABLE 123 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 164
  • TABLE 124 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 165
  • TABLE 125 SOUTH KOREA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 165
  • TABLE 126 SOUTH KOREA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 165
  • TABLE 127 SOUTH KOREA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 166
  • TABLE 128 SOUTH KOREA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 166
  • TABLE 129 SOUTH KOREA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 166
  • TABLE 130 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION) 167
  • TABLE 131 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 167
  • TABLE 132 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION) 167
  • TABLE 133 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 168
  • TABLE 134 SOUTH KOREA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 168
  • TABLE 135 SOUTH KOREA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 168
  • TABLE 136 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 168
  • TABLE 137 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION) 169
  • TABLE 138 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 169
  • TABLE 139 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 170
  • TABLE 140 SINGAPORE MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 170
  • TABLE 141 SINGAPORE OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 170
  • TABLE 142 SINGAPORE ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 171
  • TABLE 143 SINGAPORE OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 171
  • TABLE 144 SINGAPORE THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 171
  • TABLE 145 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION) 172
  • TABLE 146 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 172
  • TABLE 147 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION) 172
  • TABLE 148 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 173
  • TABLE 149 SINGAPORE ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 173
  • TABLE 150 SINGAPORE PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 173
  • TABLE 151 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 173
  • TABLE 152 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION) 174
  • TABLE 153 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 174
  • TABLE 154 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 175
  • TABLE 155 MALAYSIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 175
  • TABLE 156 MALAYSIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 175
  • TABLE 157 MALAYSIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 176
  • TABLE 158 MALAYSIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 176
  • TABLE 159 MALAYSIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 176
  • TABLE 160 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION) 177
  • TABLE 161 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 177
  • TABLE 162 MALAYSIA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 177
  • TABLE 163 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION) 177
  • TABLE 164 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 178
  • TABLE 165 MALAYSIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 178
  • TABLE 166 MALAYSIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 178
  • TABLE 167 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 178
  • TABLE 168 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION) 179
  • TABLE 169 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 179
  • TABLE 170 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 180
  • TABLE 171 THAILAND MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 180
  • TABLE 172 THAILAND OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 180
  • TABLE 173 THAILAND ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 181
  • TABLE 174 THAILAND OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 181
  • TABLE 175 THAILAND THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 181
  • TABLE 176 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION) 182
  • TABLE 177 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 182
  • TABLE 178 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION) 182
  • TABLE 179 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 183
  • TABLE 180 THAILAND ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 183
  • TABLE 181 THAILAND PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 183
  • TABLE 182 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 183
  • TABLE 183 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION) 184
  • TABLE 184 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 184
  • TABLE 185 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 185
  • TABLE 186 INDONESIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 185
  • TABLE 187 INDONESIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 185
  • TABLE 188 INDONESIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 186
  • TABLE 189 INDONESIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 186
  • TABLE 190 INDONESIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 186
  • TABLE 191 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION) 187
  • TABLE 192 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 187
  • TABLE 193 INDONESIA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 187
  • TABLE 194 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION) 187
  • TABLE 195 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 188
  • TABLE 196 INDONESIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 188
  • TABLE 197 INDONESIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 188
  • TABLE 198 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 188
  • TABLE 199 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION) 189
  • TABLE 200 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 189
  • TABLE 201 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 190
  • TABLE 202 PHILIPPINES MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 190
  • TABLE 203 PHILIPPINES OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 190
  • TABLE 204 PHILIPPINES ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 191
  • TABLE 205 PHILIPPINES OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 191
  • TABLE 206 PHILIPPINES THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 191
  • TABLE 207 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION) 192
  • TABLE 208 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 192
  • TABLE 209 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION) 192
  • TABLE 210 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 193
  • TABLE 211 PHILIPPINES ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 193
  • TABLE 212 PHILIPPINES PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 193
  • TABLE 213 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 193
  • TABLE 214 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION) 194
  • TABLE 215 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 194
  • TABLE 216 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 195
  • TABLE 217 VIETNAM MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 195
  • TABLE 218 VIETNAM OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 195
  • TABLE 219 VIETNAM ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 196
  • TABLE 220 VIETNAM OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 196
  • TABLE 221 VIETNAM THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 196
  • TABLE 222 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION) 197
  • TABLE 223 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 197
  • TABLE 224 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION) 197
  • TABLE 225 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 198
  • TABLE 226 VIETNAM ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 198
  • TABLE 227 VIETNAM PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 198
  • TABLE 228 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 198
  • TABLE 229 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION) 199
  • TABLE 230 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 199
  • TABLE 231 REST OF ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION) 200

LIST OF FIGURES

  • FIGURE 1 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET : SEGMENTATION 33
  • FIGURE 2 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DATA TRIANGULATION 36
  • FIGURE 3 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DROC ANALYSIS 37
  • FIGURE 4 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS 38
  • FIGURE 5 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY RESEARCH ANALYSIS 38
  • FIGURE 6 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: INTERVIEW DEMOGRAPHICS 39
  • FIGURE 7 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DBMR POSITION GRID 41
  • FIGURE 8 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: VENDOR SHARE ANALYSIS 43
  • FIGURE 9 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: END USER COVERAGE GRID 44
  • FIGURE 10 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SEGMENTATION 48
  • FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029 49
  • FIGURE 12 INCREASED INCIDENCE OF ALCOHOL USE DISORDERS AND RISE IN PRODUCT APPROVALS IS EXPECTED TO DRIVE ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET FROM 2022 TO 2029 50
  • FIGURE 13 TYPE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET FROM 2022 & 2029 50
  • FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET 61
  • FIGURE 15 INCIDENCE OF ALCOHOL CONSUMPTION IN 2019 62
  • FIGURE 16 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, 2021 71
  • FIGURE 17 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, 2022-2029 (USD MILLION) 72
  • FIGURE 18 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, CAGR (2022-2029) 72
  • FIGURE 19 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, LIFELINE CURVE 73
  • FIGURE 20 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, 2021 81
  • FIGURE 21 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, 2022-2029 (USD MILLION) 81
  • FIGURE 22 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, CAGR (2022-2029) 82
  • FIGURE 23 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, LIFELINE CURVE 83
  • FIGURE 24 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, 2021 91
  • FIGURE 25 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION) 92
  • FIGURE 26 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, CAGR (2022-2029) 92
  • FIGURE 27 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, LIFELINE CURVE 93
  • FIGURE 28 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, 2021 98
  • FIGURE 29 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, 2022-2029 (USD MILLION) 99
  • FIGURE 30 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, CAGR (2022-2029) 99
  • FIGURE 31 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, LIFELINE CURVE 100
  • FIGURE 32 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, 2021 104
  • FIGURE 33 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION) 105
  • FIGURE 34 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029) 105
  • FIGURE 35 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 106
  • FIGURE 36 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, 2021 112
  • FIGURE 37 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, 2022-2029 (USD MILLION) 113
  • FIGURE 38 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, CAGR (2022-2029) 113
  • FIGURE 39 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, LIFELINE CURVE 114
  • FIGURE 40 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, 2021 118
  • FIGURE 41 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, 2022-2029 (USD MILLION) 119
  • FIGURE 42 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, CAGR (2022-2029) 119
  • FIGURE 43 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, LIFELINE CURVE 120
  • FIGURE 44 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, 2021 126
  • FIGURE 45 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 127
  • FIGURE 46 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 127
  • FIGURE 47 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 128
  • FIGURE 48 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SNAPSHOT (2021) 135
  • FIGURE 49 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021) 137
  • FIGURE 50 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2022 & 2029) 137
  • FIGURE 51 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021 & 2029) 138
  • FIGURE 52 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE (2022-2029) 138
  • FIGURE 53 ASIA PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY SHARE 2021 (%) 200
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!